Samsung Bioepis to Present Post-hoc Analysis of Phase 3

Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May ...

Related Keywords

Spain ,Madrid ,Eculizumab Biosimilar ,Younsoo Kim ,Samsung Bioepis ,Jihyun Han ,Paola Russo ,Hyejin Kim ,Hus Laboratory Monitoring ,Lifecycle Safety Team Leader At Samsung Bioepis ,Linkedin ,European Hematology Association ,Laboratory Monitoring ,Samsung Bioepis Co Ltd ,European Union ,European Medicines Agency ,European Commission ,Alexion Pharmaceuticals ,Hybrid Congress ,Vice President ,Lifecycle Safety Team Leader ,Transfusion Avoidance ,Reference Eculizumab ,Post Hoc Analysis ,Pivotal Phase ,Jun Ho Jang ,Jihye Park ,Product Characteristics ,Soliris Product ,Accessed May ,Epysqli Product ,